Project Grant R41HL182396
Award Date 8/10/26
Completion Date 7/31/27
Dollars Obligated $498K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Mason, OH 45040, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded The Ohio State University a $1.535 million cooperative agreement (UG3HL175260) on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct the WINDSURFER trial, a multi-site clinical study comparing non-invasive respiratory support strategies for acute hypoxemic respiratory failure in emergency departments. The trial will evaluate two competing non-invasive respiratory support approaches: non-invasive...
- The National Heart Lung and Blood Institute awarded Fascia Sleep Incorporated $417,686 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate a wearable device for at-home sleep apnea diagnosis. Fascia is developing the Fascia Sleep Ecosystem, a home-based monitoring system integrating flexible electronics and fabric-based sensing technology into a wearable mask that captures clinical-grade physiological data comparable to Level II...
- The National Heart, Lung, and Blood Institute awarded $316,609 to Remplenish, Inc. on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel myofunctional nipple device for preventing obstructive sleep apnea in infants. The recipient will design and validate a low-risk, low-burden device that delivers myofunctional therapy—oropharyngeal exercises integrated into infant bottle feeding—as a non-invasive first-line treatment and preventive measure...
- The National Heart, Lung, and Blood Institute awarded Vivamed, Inc. $257,015 on June 15, 2026, to develop a wirelessly powered, battery-free hypoglossal nerve stimulator for treating obstructive sleep apnea under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds development of a minimally invasive implantable device designed to address limitations of existing hypoglossal nerve stimulation systems. The device will integrate electromyography sensors for real-time muscle...
- The National Heart, Lung, and Blood Institute awarded The Trustees of the University of Pennsylvania $1.542 million on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to improve understanding of sleep apnea pathogenesis using novel imaging techniques during sleep. The research combines drug-induced sleep endoscopy (DISE) with dynamic magnetic resonance imaging (MRI) to characterize upper airway anatomy and the mechanisms of airway collapse during sleep. The...
- The National Heart, Lung, and Blood Institute awarded $499,932 to Safebvm Corp. on September 17, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to integrate capnography sensing into the SOTAIR device for standardizing manual ventilation technique and improving patient outcomes. SOTAIR is a lightweight (14 grams), battery-free attachment device compatible with all commercially available bag-valve masks that employs flow-blocking and pressure-control mechanisms to...
- The National Heart, Lung, and Blood Institute awarded Resuscitation Innovations LLC $396,098 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and test an adjustable-pressure impedance threshold device for cardiac arrest resuscitation and post-resuscitation care. The recipient will refine the design of the Adjustable Pressure for Emergency Care (APEC) device, a dual-setting airway device with selectable cracking pressures of -6 and -12 centimeters of...
- The National Heart, Lung, and Blood Institute awarded $920,616 to Vena Vitals Inc. on September 24, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop VeriSleep, a wearable device for continuous, non-invasive blood pressure monitoring during sleep as a cardiovascular biomarker. The project addresses the technological gap in continuous blood pressure measurement during sleep, where current intermittent cuff-based monitors leave lengthy unmonitored gaps despite the...
- The National Heart, Lung, and Blood Institute awarded Voyageur Medtech, Corp. $314,344 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel sensor and audible alarming device that alerts caregivers when a tracheostomy tube has been obstructed or decannulated. The project addresses a critical clinical need in pediatric tracheostomy management. Approximately 100,000 patients receive tracheostomy procedures annually in the United States,...
- The National Heart, Lung, and Blood Institute awarded Berendo Scientific LLC $583,718 in project grant funding on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to optimize and evaluate the SLEEPFLEX head and neck exercise program for treating mild to moderate obstructive sleep apnea. The recipient will develop a non-invasive treatment delivering targeted head and neck exercises via smartphone application (iOS and Android) with instructional videos and...